VIR
Vir Biotechnology, Inc.
There isn't enough reported data to score VIR yet.
VIR Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Under pressure | |
| Under pressure | |
| Strong |
VIR's revenue and balance sheet are currently strong, but its profitability and cash flow are under pressure.
VIR PE Valuation
VIR has no meaningful PE right now: it lost money over the past year.
VIR Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Strong decline | |
| -- | |
| Limited | |
| Low |
Analysts expect VIR's losses to grow, with revenue declining. However, they disagree widely on these estimates.
VIR Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2026 | -$1.86 | +$2.15 |
| Q1 2026 | -$3.13 | +$1.10 |
| Q4 2025 | -$3.16 | +$0.67 |
| Q3 2025 | -$3.62 | +$0.30 |
| Q2 2025 | -$4.01 | -$0.43 |
| Q1 2025 | -$4.23 | -$0.22 |
| Q4 2024 | -$3.83 | +$0.76 |
| Q3 2024 | -$3.92 | +$0.55 |
VIR is still losing money, but far less than before: $1.86 per share over the past year, against $4.59 at its worst in late 2023.
VIR Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2026 | $238.9M | +19583% |
| Q4 2025 | $64.1M | +418% |
| Q3 2025 | $240K | -90% |
| Q2 2025 | $1.2M | -61% |
| Q1 2025 | $3M | -95% |
| Q4 2024 | $12.4M | -26% |
| Q3 2024 | $2.4M | -9.8% |
| Q2 2024 | $3.1M | -19% |
VIR's revenue is recovering but still below its 2022 peak: $239M last quarter, up 19583% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2026 | 31% | +9785 points |
| Q4 2025 | -75% | +872 points |
| Q3 2025 | -72268% | -62549 points |
| Q2 2025 | -9754% | -4596 points |
| Q1 2025 | -4602% | -4460 points |
| Q4 2024 | -947% | -119 points |
| Q3 2024 | -9719% | -2643 points |
| Q2 2024 | -5159% | +509 points |
VIR's operating margin was 31% last quarter, up 4633 points from the same quarter a year ago.
VIR Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2026 | $123.3M | +$246.1M |
| Q1 2026 | -$132.8M | -$53M |
| Q4 2025 | -$26.2M | +$63.8M |
| Q3 2025 | -$167.9M | +$5.9M |
| Q2 2025 | -$122.8M | -$44.2M |
| Q1 2025 | -$79.7M | +$31.5M |
| Q4 2024 | -$90M | +$19.4M |
| Q3 2024 | -$173.8M | -$14.3M |
VIR has burned cash in most quarters: −$204M over the past year, against −$466M the year before.
VIR Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +15% | +21.5M shares |
| 1 year | +22% | +30.4M shares |
| 3 years | +26% | +34.8M shares |
| 5 years | +26% | +35.1M shares |
| Available history | +56% | +60.5M shares |
VIR has 169M diluted shares, up 22% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2026 | — |
| Q2 2022 | — |
VIR Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q4 2022 | -1.0x | Net Cash |
| Q3 2022 | -0.6x | Net Cash |
| Q2 2022 | -1.1x | Net Cash |
| Q1 2022 | -0.5x | Net Cash |
| Q4 2021 | -0.8x | Net Cash |
VIR has more cash than debt.
VIR Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 63.2 | Neutral |
| Stochastic | 76.5 | Neutral |
VIR's weekly RSI is 63 (neutral) and its Stochastic is 76 (neutral).
VIR PE vs Healthcare Sector
| Metric | VIR | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
VIR has no meaningful PE right now: it lost money over the past year.
VIR Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $11.2 | 8.1% above |
| 20 week MA | $10.4 | 17% above |
| 50 week MA | $9.12 | 33% above |
| 100 week MA | $7.75 | 56% above |
| 200 week MA | $10.7 | 13% above |
VIR has climbed back above all five of its weekly moving averages, and it's now 13% above its 200-week average.
VIR Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $12.4 | $29.5 | +139% |
| 2021 | $29.5 | $41.8 | +41% |
| 2022 | $41.8 | $25.7 | -38% |
| 2023 | $25.7 | $10.1 | -61% |
| 2024 | $10.1 | $7.47 | -26% |
| 2025 | $7.47 | $6.00 | -20% |
| 2026 YTD | $6.00 | $12.1 | +102% |
VIR has finished four years in a row lower, and it's up 102% so far in 2026.